Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be at least 60 years old
- 80% of new participants enrolled through the clinic will have symptoms such as forgetfulness, mild memory problems, mild dementia, or Alzheimer's disease, as noted in their medical records or by their doctor
- People already taking part in a related study called SEABIRD are also welcome to join, whatever their memory or thinking abilities
Who may not be able to join:
- People who are unable to do basic daily tasks on their own — such as eating, bathing, getting dressed, moving around, or using the toilet — because of memory or thinking problems
- People who have uncontrolled hepatitis B, hepatitis C, or HIV at the time their blood is collected
- People who are currently taking a medication designed to treat or slow the progression of Alzheimer's disease
- People who have had a blood transfusion within the last three months
- People who are unwilling or unable to take part in all of the study activities
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Randall Bateman, MD, Washington University School of Medicine
Phone: 314-747-4857
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Area under the curve (AUC) of plasma amyloid-beta 42/40 in predicting amyloid PET status; Area under the curve (AUC) of plasma %p-tau217 in predicting amyloid PET status; Area under the curve (AUC) of plasma p-tau217 in predicting tau PET status; Area under the curve (AUC) of plasma p-tau205 in predicting tau PET status; Area under the curve (AUC) of plasma neurofilament light in predicting tau PET status; Area under the curve (AUC) of plasma %p-tau205 in predicting clinical diagnosis; Area under the curve (AUC) of plasma %p-tau217 in predicting clinical diagnosis; Area under the curve (AUC) o...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.